Crossmark

Pimavanserin use in a movement disorders clinic: a single-center experience

Crossref DOI link: https://doi.org/10.1007/s10072-018-3500-5

Published Online: 2018-07-21

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mahajan, Abhimanyu https://orcid.org/0000-0001-8807-6672
Bulica, Bisena

Ahmad, Ayesha

Kaminski, Patricia

LeWitt, Peter

Taylor, Danette

Krstevska, Shana

Patel, Neepa
License Information

Text and Data Mining valid from 2018-07-21
More Information

Article History

Received: 16 May 2018

Accepted: 11 July 2018

First Online: 21 July 2018

Compliance with ethical standards

: This study was approved by the Henry Ford Institutional Review Board.

: Abhimanyu Mahajan, Bisena Bulica, Ayesha Ahmad, Patricia Kaminski, Danette Taylor, and Shana Krstevska report no conflicts of interest. Dr. LeWitt is a consultant for Acorda Therapeutics; Adamas; Britannia; Intec Pharma; Jazz Pharmaceuticals; Lundbeck; Merz; NeuroDerm Ltd.; Pfizer; Prexton; Sage; Scion; Sunovion; SynAgile. He receives lecture fees from Acadia; Lundbeck; US WorldMeds. He also has research grant support from AcordaTherapeutics; Adamas; Bioelectron Technology Corporation; Biotie Therapies; Intec Pharma; Lundbeck; Michael J. Fox Foundation for Parkinson’s Research; Parkinson Study Group; Sunovion; US WorldMeds. Dr. Patel has received honoraria as a consultant for Acadia pharmaceuticals and as a speaker for Teva pharmaceuticals.